전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
edoksabāns ir izplūdes transportproteīna p-gp substrāts.
edoxaban is a substrate for the efflux transporter p-gp.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
enzalutamīds nav transportproteīna p-glikoproteīna vai bcrp substrāts.
enzalutamide is not a substrate of the efflux transporters p-gp or bcrp.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
dabigatrāna eteksilāts ir izplūdes transportproteīna p-gp substrāts.
dabigatran etexilate is a substrate for the efflux transporter p-gp.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
Šīs mijiedarbības pamatā var būt membrānas transportproteīna p glikoproteīna inhibīcija.
this interaction may be explained by an inhibition of the membrane transport protein, p-glycoprotein.
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
in vitro dati liecina, ka enzalutamīds var būt transportproteīna p-glikoproteīna inhibitors.
in vitro data indicate that enzalutamide may be an inhibitor of the efflux transporter p-gp.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
migalastats nav mdr1 vai bcrp substrāts un nav bcrp, mdr1 vai cilvēka izplūdes transportproteīna bsep inhibitors.
migalastat is not a substrate for mdr1 or bcrp, nor is it an inhibitor of bcrp, mdr1, or bsep human efflux transporters.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
in vitro nav novērota nozīmīga telaprevīra izraisīta organisko katjonu transportproteīna oct-2 inhibīcija.
no relevant inhibition by telaprevir of the organic cation transporter (oct) oct2 was observed in vitro.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
izplūdes transportproteīna p-gp substrāts ir nevis dabigatrāns, bet tā pirmszāles dabigatrāna eteksilāts.
the pro-drug dabigatran etexilate but not dabigatran is a substrate of the efflux transporter p-gp.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
amiodarons ir izplūdes transportproteīna p- glikoproteīna inhibitors, bet dabigatrāna eteksilāts – šī transportproteīna substrāts.
amiodarone is an inhibitor of the efflux transporter p-glycoprotein and dabigatran etexilate a substrate of this transporter.
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
vokanamet ir kombinācija, kuru veido divas perorālas glikozes līmeni pazeminošas zāles ar atšķirīgu un savstarpēji papildinošu darbības mehānismu: sglt2 transportproteīna inhibitors kanagliflozīns un biguanīdu grupas līdzeklis metformīna hidrohlorīds.
vokanamet combines two oral glucose-lowering medicinal products with different and complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: canagliflozin, an inhibitor of sglt2 transporter, and metformin hydrochloride, a member of the biguanide class.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
perorāla ciklosporīna a (pa 15 mg/ kg), transportproteīnu abcb1 (p- gp) un abcg1 (mrp- 1), kā arī metabolisma enzīma cyp3a4 inhibitora lietošana 4 stundu laikā pēc iekšķīgas topotekāna lietošanas palielina pēc devas normalizētu topotekāna laktona un kopējā topotekāna auc0- 24h atbilstoši aptuveni 2, 0 un 2, 5 reizes (skatīt apakšpunktu 4. 5).
administration of oral cyclosporine a (15 mg/ kg), an inhibitor of transporters abcb1 (p-gp) and abcc1 (mrp-1) as well as the metabolising enzyme cyp3a4, within 4 hours of oral topotecan increased the dose normalised auc0-24h of topotecan lactone and total topotecan approximately 2.0- and 2.5-fold respectively (see section 4.5).
마지막 업데이트: 2012-04-10
사용 빈도: 4
품질: